vimarsana.com

Latest Breaking News On - Quantitative myasthenia gravis - Page 1 : vimarsana.com

Investigational Drug for Myasthenia Gravis Shows Promise in Improving Symptoms

Batoclimab, an investigational drug for myasthenia gravis, may significantly improve activities of daily living among patients.

China
Chinese
Drug-administration
Myasthenia-gravis-foundation-of-america
Chinese-han
Myasthenia-gravis-foundation
Quantitative-myasthenia-gravis
Myasthenia-gravis-activities
Daily-living

Promising Results for Investigational Myasthenia Gravis Drug

Treatment with batoclimab resulted in a nearly 60% sustained improvement in daily activities in adult patients with generalized myasthenia gravis.

Sweden
China
Stockholm
Shanghai
Huashan
Henan
Chinese
Fredrik-piehl
Mg-foundation-of-america
National-center
Huashan-rare-disease-centre
Huashan-hospital-of-fudan-university

Phase 2 Results Show Safety, Dose-Dependent Improvements in Function With Nipocalimab in gMG

Based on data from the study, a phase 3 confirmatory trial is underway for the humanized monoclonal antibody.

Myasthenia-gravis-activities
Daily-living
Quantitative-myasthenia-gravis
Myasthenia-gravis-quality

Zilbrysq Now Available for Generalized Myasthenia Gravis

Zilbrysq® (zilucoplan) is now available for the treatment of generalized myasthenia gravis in adult patients who are AChR antibody positive.

Daily-living
Quantitative-myasthenia-gravis

Low-Dose Rituximab Effective Against MuSK-Positive MG in New Analysis

Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.

Neurosci-lett
Michael-benatar
Shanxi-medical-university
Myasthenia-gravis-foundation-of-america
Neurology-department-of-first-hospital
Image-credit
Neuroscience-letters
Neurology-department
First-hospital
Myasthenia-gravis-foundation
America-post-intervention-status
Quantitative-myasthenia-gravis

vimarsana © 2020. All Rights Reserved.